TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00089011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00308282

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV (in vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
Study: NCT03259308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Participants will receive 1 mL of ontamalimab sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Participants will receive 1 mL of ontamalimab sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 mL of sterile aqueous buffered solution.
Study: NCT00996177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem
Description: 40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Morphine Patient-Controlled Analgesia (IV PCA)
Description: 20mg/2hr (240 mg during 24 hours)
Study: NCT03297827

Intervention type: OTHER
Intervention: Serum and Urine measurement of cytokines.
Description: To evaluate serum cytokine levels and identifying serum inflammatory markers (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001) in patients with acute ischemic \& hemorrhagic stroke.

Intervention type: OTHER
Intervention: Serum and Urine measurement of cytokines.
Description: To evaluate serum cytokine levels and identifying serum inflammatory markers (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001) in patients with acute ischemic \& hemorrhagic stroke.
Study: NCT04701320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional glass ionomer
Description: Conventional glass ionomer with enhanced mechanical and esthetic proberties

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano hydroxyapatite reinforced glass ionomer
Description: Nanohydroxyapatite reinforced glass ionomer restorative material with enhanced mechanical proberties and chemical adhesion to tooth structure
Study: NCT01574560

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Information regarding secondhand smoke and creating a healthy home environment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Receives brochure and counseling sessions focusing on changing smoking behaviors and/or other health behaviors.
Study: NCT00105508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarizotan
Description: Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks.
Study: NCT01594099

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: irradiation
Description: EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposome paclitaxel
Description: EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy.
Study: NCT03918993

Intervention type: DRUG
Intervention: Tadalafil 5mg tablet
Description: Once-a-day 5 mg dose of tadalafil for 8 weeks
Study: NCT01771302

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss
Description: It is a bone substitute of bovine origin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: calcium phosphate ceramic
Description: It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature
Study: NCT00105508

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.
Study: NCT01594684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.)
Description: balloon inflation
Study: NCT01950715

Intervention type: DEVICE
Group type: OTHER
Intervention: sacral nerve stimulation
Description: Sacral nerve stimulation
Study: NCT01444378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems
Description: Stenting of the Superficial Femoral Artery (SFA) and/or proximal popliteal artery using either of these devices.
Study: NCT02554877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: study drug to be given as an oral tablet at 30, 60 or 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: study drug to be given as an oral tablet at 30, 60 or 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: study drug to be given as an oral tablet at 30, 60 or 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study: NCT01395238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathers Supporting Success in preschoolers
Description: Group-based, 8 weekly session for 2.0 hours/week.
Study: NCT00811226

Intervention type: DRUG
Intervention: olmesartan medoxomile alone or combined with hydrochlorothiazide,
Description: olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
Study: NCT02506530

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensive decongestive treatment
Description: intensive decongestive treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intensive decongestive treatment
Description: intensive decongestive treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellu M6
Description: Use of Cellu M6

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellu M6
Description: Use of Cellu M6
Study: NCT00847561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based CBT
Description: Eight, 1-hour weekly sessions with a trained clinician.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information Monitoring
Description: Packet providing information on strategies for coping with anxiety
Study: NCT04291157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CVD risk estimation incorporating the PRS and guideline based preventive interventions.
Description: Total CVD risk estimation using SCORE plus PRS and European Society of Cardiology (ESC) CVD prevention guideline based interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard GP care
Description: Usual GP care (opportunistic CVD prevention)
Study: NCT02950129

Intervention type: OTHER
Group type: OTHER
Intervention: SIJ pain diagnostic tests
Description: The subjects will undergo a specific physical exam of tests reported to be diagnostic of sacroiliac joint (SIJ) pain prior to receiving the routine injection in the SIJ; all tests will be repeated after the SIJ injection
Study: NCT01475201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step count prescription
Description: Treating physicians will provide a pedometer, pedometer log, and step count prescription. The aim is a net increase of at least 3,000 steps/day over one year. The time frame for this increase will be 10 months for sedentary participants (\<5,000 steps/day), 7 months for low active participants (5,000-7,499 steps/day), and 5 months for somewhat active participants (7,500-9,999 steps/day). If goals are not met, the doctor and participant will review barriers and facilitators, and a more individualized prescription will be formulated (e.g. lower incremental step count targets or slower rate of dose escalation). For participants who meet goals, the doctor and participant will together decide whether to aim for a further increase.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week).
Study: NCT01288183

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham condition as delivered by the stimulator study mode (2mA during 40s and brief current pulses until the end of the stimulation) 20 minutes, 10 sessions, 2 per day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: anodal tDCS applied over the right DLPFC 2mA, 20minutes, 10 sessions, 2 per day
Study: NCT03392129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ai Chi
Description: Children in the intervention group will perform 12 sessions (twice a week 40 minutes each session) of treatment with the Ai Chi Method, and educational intervention in relation to asthma.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma education
Description: Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
Study: NCT02835729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod Freebase
Description: IDO pathway inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod HCL F1
Description: IDO pathway inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod HCL F2
Description: IDO pathway inhibitor
Study: NCT02760628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The First Twenty (TF20)
Description: TF20 is an online wellness program for firefighters focused on improving cardiovascular risk factors through behavioral changes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Life Simple 7 (LS7)
Description: LS7 is a wellness program designed and implemented by the American Heart Association focused on improving cardiovascular health.
Study: NCT02650011

Intervention type: OTHER
Intervention: Acute deterioration of liver function
Description: development of new ascites within 4 weeks or re-emergence of ascites who have previous well controlled ascites (greater than or equal to grade 2 or 3; International ascites club criteria) development of hepatic encephalopathy development of gastrointestinal hemorrhage development of jaundice (serum bilirubin greater than or equal to 3mg/dl) development of bacterial infection
Study: NCT03240640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training
Description: IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Endurance Training
Description: IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
Study: NCT02146781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection
Description: Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intradermal injection using the Biojector 2000 devibe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection
Description: Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intradermal injection using the Biojector 2000 devibe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Control
Description: The subjects in Cohort 1 will receive four doses of saline control 14 days apart, beginning Day 0. Each dose will be delivered as four separate injections of 0.200 mL volumes administered Intradermally (ID) using the needless Biojector 2000 device in separate skin sites. The use of the four 0.200 mL volumes is necessitated in order to compare the skin test sites to the number of sites in Cohorts 2 (4 sites per dose) and Cohort 3 (2 sites per dose). The multiple intradermal administration sites per dose are because of the dilute vaccine material (2.7 mg/mL).
Study: NCT00308620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chloroquine phosphate
Description: 250mg or 500mg PO (by mouth) QDay

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 8 weeks
Study: NCT00651040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
Study: NCT02117089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation; Rehabilitation Robot
Description: The recruited subjects will receive 20-session device assisted upper limb training with an intensity of 3 to 5 sessions/week, which will be finished within 7 consecutive weeks. In each session, the subjects will conduct the system assisted and task-oriented upper limb training for 1.5 hours.
Study: NCT03563534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Diamine Fluoride
Description: Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, and apply 38% silver diamine fluoride.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer
Description: Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, apply resin modified glass ionomer.
Study: NCT04170881

Intervention type: OTHER
Intervention: Exposed/non exposed - Epidemiology
Description: visit of daycares and environmental measurement will be performed

Intervention type: OTHER
Intervention: Exposed/non exposed - Epidemiology
Description: visit of daycares and environmental measurement will be performed
Study: NCT00546351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
Study: NCT00960557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A1 Diphosphate (OXi4503)
Description: OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT05631951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone transport through induced membrane
Description: Debridement done followed by external fixator and cement application to be followed by removal of cement (after 6 weeks) and start bone transport

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone transport
Description: Debridement done then external fixator was applied then bone transport started.
Study: NCT02075164

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: High oral Fructose challenge (150g per day for 56 days)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: High oral Fructose challenge (150g per day for 56 days)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)
Study: NCT04316481

Intervention type: DEVICE
Group type: OTHER
Intervention: AngelMed Guardian System
Description: The AngelMed Guardian System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events. The Guardian System is indicated as an adjunct to patient recognized symptoms.
Study: NCT03271489

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elagolix Placebo
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2/NETA
Description: Capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E2/NETA Placebo
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Tablets
Study: NCT00104104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
Study: NCT03414359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine
Description: 2% Lidocaine using a combined spinal-epidural (CSE)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Chloroprocaine
Description: 3% Chloroprocaine using a combined spinal-epidural (CSE)
Study: NCT03399890

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological physical exam
Description: Neurological physical exam is performed in all patients at the OR table, immediately after the operation.
Study: NCT04024020

Intervention type: OTHER
Intervention: lumbar puncture
Description: Subjects will have a lumbar puncture to collect cerebrospinal fluid collection

Intervention type: OTHER
Intervention: lumbar puncture
Description: Subjects will have a lumbar puncture to collect cerebrospinal fluid collection
Study: NCT03059160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tridecanoic Acid
Description: 3 times daily oral doze of the drug for 20 weeks with 4 weeks of baseline and 4 weeks of washout